These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 29807194)

  • 1. Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction.
    Veron-Esquivel D; Batiz-Armenta F; Cazares-Diazleal AC; Oviedo-Moguel S; Jarvio-Fernandez SM; Arce-Gonzalez JM; Ivey-Miranda JB
    Hellenic J Cardiol; 2019; 60(5):296-302. PubMed ID: 29807194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial.
    Li Y; Li J; Wang B; Jing Q; Zeng Y; Hou A; Wang Z; Liu A; Zhang J; Zhang Y; Zhang P; Jiang D; Liu B; Fan J; Zhang J; Li L; Su G; Yang M; Jiang W; Qu P; Zeng H; Li L; Qiu M; Ru L; Chen S; Zhou Y; Qiao S; Stone GW; Angiolillo DJ; Han Y;
    JAMA Cardiol; 2024 Jun; 9(6):523-531. PubMed ID: 38630489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
    Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
    Valgimigli M; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; Choi JW; Campo G; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Zheng Y; Mehran R;
    J Am Coll Cardiol; 2021 Nov; 78(21):2060-2072. PubMed ID: 34794687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH;
    Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
    Gajanana D; Rogers T; Weintraub WS; Kolm P; Iantorno M; Khalid N; Chen Y; Shlofmitz E; Khan JM; Musallam A; Ben-Dor I; Satler LF; Zhang C; Torguson R; Waksman R
    Am J Cardiol; 2020 Jun; 125(11):1631-1637. PubMed ID: 32273057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry.
    Håkansson A; Koul S; Omerovic E; Andersson J; James S; Agewall S; Mokhtari A; van Der Pals J; Wester A; Szummer K; Jernberg T; Erlinge D; Mohammad MA
    J Am Heart Assoc; 2024 Jul; 13(13):e034709. PubMed ID: 38934886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.
    Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL
    Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy.
    Choi SY; Kim MH; Cho YR; Sung Park J; Min Lee K; Park TH; Yun SC
    Circ Cardiovasc Interv; 2018 Dec; 11(12):e006837. PubMed ID: 30545256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
    JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
    Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
    Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
    Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
    Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline.
    Wang HY; Dou KF; Wang Y; Yin D; Xu B; Gao RL
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):663-675. PubMed ID: 32601780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
    Shah RR; Pillai A; Omar A; Zhao J; Arora V; Kapoor D; Poommipanit P
    Catheter Cardiovasc Interv; 2017 Mar; 89(4):E99-E103. PubMed ID: 27184930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Yeh RW; Kereiakes DJ; Steg PG; Cutlip DE; Croce KJ; Massaro JM; Mauri L;
    J Am Coll Cardiol; 2017 Oct; 70(18):2213-2223. PubMed ID: 29073947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease.
    Mankerious N; Toelg R; Vogel B; Sartori S; Angiolillo DJ; Vranckx P; Feng Y; de la Torre Hernandez JM; Krucoff MW; Bhatt DL; Spirito A; Cao D; Chehab BM; Kunadian V; Maksoud A; Picon H; Sardella G; Thiele H; Varenne O; Windecker S; Richardt G; Valgimigli M; Mehran R
    Am J Cardiol; 2024 Aug; 225():25-34. PubMed ID: 38871156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    Yeh RW; Secemsky EA; Kereiakes DJ; Normand SL; Gershlick AH; Cohen DJ; Spertus JA; Steg PG; Cutlip DE; Rinaldi MJ; Camenzind E; Wijns W; Apruzzese PK; Song Y; Massaro JM; Mauri L;
    JAMA; 2016 Apr; 315(16):1735-49. PubMed ID: 27022822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.